Clinical characteristics and stratification of the cerebrovascular accident risk among patients with atrial fibrillation in Colombia, 2011-2016

References

• Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014 Feb 25;129(8):837–847.
   PubMed Web of Science ®Google Scholar
• Lip GY, Fauchier L, Freedman SB, et al. Atrial fibrillation. Nat Rev Dis Primers. 2016 Mar;31(2):16016.
   Google Scholar
• Rosselli D, Rodríguez AJ, García ÁA, et al. Prevalencia de fibrilación auricular en un hospital universitario colombiano. Rev Col Cardiol. 2013;20(6):383–385.
   Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Rev Esp Cardiol (English Ed). 2017 Jan;70(1):50.
   PubMed Web of Science ®Google Scholar
• Lip GY, Laroche C, Boriani G, et al. Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational research programme atrial fibrillation (EORP-AF) pilot general registry. Europace. 2015 Feb;17(2):194–206.
   PubMed Web of Science ®Google Scholar
• Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2016 Jul 14;13(8):501.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1–76.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PloS One. 2013;8(5):e63479.
   PubMed Web of Science ®Google Scholar
• Franco JS, Vizcaya D. Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review. Pharmacol Res Perspect. 2020 Oct;8(5):e00661.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692–694.
   PubMed Web of Science ®Google Scholar
• Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015 Nov;13(11):2119–2126.
   PubMed Web of Science ®Google Scholar
• Cortés-Ramírez JM, Cortés-de la Torre RA, de la Torre-murillo R, et al. Fibrilación auricular. Estratificación, tratamiento con anticoagulantes y seguimiento. Medicina Interna De México. 2014;30(2):133–139.
   Google Scholar
• Lara-Vaca S, Cordero-Cabra A, Martínez-Flores E, et al. Registro Mexicano de Fibrilación Auricular (ReMeFa). Gaceta Médica De México. 2014;150(s1):48–59.
   PubMedGoogle Scholar
• Dogan V, Basaran O, Biteker M, et al. Analysis of geographical variations in the epidemiology and management of non-valvular atrial fibrillation: results from the RAMSES registry. Anatol J Cardiol. 2017 Oct;18(4):273–280.
   PubMed Web of Science ®Google Scholar
• Pinto DA, Sánchez-Vallejo CA, Pedraza AL, et al. Descripción de los pacientes con fibrilación auricular no valvular que ingresan al servicio de urgencias. Rev Col Cardiol. 2016;23(4):270–276.
   Google Scholar
• Roa LF, Mendoza M, Jiménez N, et al. Prevalencia y factores asociados de la discapacidad moderada y severa en pacientes con enfermedad cerebrovascular aguda y fibrilación auricular en un hospital universitario de Bogotá. Acta Neurol Colomb. 2015;31(4):391–397.
   Google Scholar
• Lee SI, Sayers M, Lip GY, et al. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. Int J Clin Pract. 2015 Nov;69(11):1341–1348.
   PubMed Web of Science ®Google Scholar
• Loikas D, Forslund T, Wettermark B, et al. Sex and gender differences in thromboprophylactic treatment of patients with atrial fibrillation after the introduction of non-vitamin K oral anticoagulants. Am J Cardiol. 2017 Oct 15;120(8):1302–1308.
   PubMed Web of Science ®Google Scholar
• Sabouret P, Depret-Bixio L, Cotte FE, et al. Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial fibrillation in general practice) database. Clin Res Cardiol. 2014 Nov;103(11):887–893.
   PubMed Web of Science ®Google Scholar
• Cea-Calvo L, Redón J, Lozano JV, et al. Prevalencia de fibrilación auricular en la población española de 60 o más años de edad. Estudio PREV-ICTUS. Rev Esp Cardiol. 2007;60(6):616–624.
   PubMedGoogle Scholar
• Gómez-Doblas JJ, Muñiz J, Martin JJA, et al. Prevalencia de fibrilación auricular en España. Resultados del estudio OFRECE. Rev Esp Cardiol. 2014;67(4):259–269.
   PubMed Web of Science ®Google Scholar
• Machado-Alba JE, García-Betancur S, Villegas-Cardona F, et al. Patrones de prescripción de los nuevos anticoagulantes orales y sus costos económicos en Colombia. Rev Col Cardiol. 2016;23(4):277–285.
   Google Scholar
• Cubillos L, Haddad A, Kuznik A, et al. Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Int J Gen Med. 2014;7:441–448.
   PubMedGoogle Scholar
• Fonseca-Centeno Z, Heredia-Vargas A, Ocampo-Téllez R, et al. Encuesta Nacional de la Situación Nutricional en Colombia 2010-ENSIN. Bogotá, DC: Instituto Colombiano de Bienestar Familiar; 2011.
   Google Scholar
• Aguilar M, Vázquez H, Sandoya E. Situación de la fibrilación auricular en Uruguay. Rev Urug Cardiol. 2017;32(1):56–64.
   Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Mora-Llabata V, Dubois-Marqués D, Roldán-Torres I, et al. Prevalencia de fibrilación auricular y características de la fibrilación auricular no valvular en la población general. Registro AFINVA. Rev Col Cardiol. 2017;24(1):26–33.
   Google Scholar
• Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro heart survey on atrial fibrillation. Eur Heart J. 2005 Nov;26(22):2422–2434.
   PubMed Web of Science ®Google Scholar
• Gamra H, Murin J, Chiang C-E, et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the international realiseAF survey. Arch Cardiovasc Dis. 2014;107(2):77–87.
   PubMed Web of Science ®Google Scholar
• Machado-Alba JE, Arias-Jaramillo DR, Gaviria-Mendoza A. Letter by Machado-Alba et al Regarding Article, “Rivaroxaban versus Dabigatran or Warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis”. Stroke. 2017 Jun;48(6):e148.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008 Nov 11;118(20):2029–2037.
   PubMed Web of Science ®Google Scholar
• Miranda H, Osorio S, Giraldo DP, et al. Tiempo en rango terapéutico (TRT) en clínica de anticoagulación. Reportes de eventos adversos y factores asociados a bajo TRT. Acta Médica Colombiana. 2016;41(1):42–48.
   Google Scholar
• Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2017 Apr;43(3):365–379.
   PubMed Web of Science ®Google Scholar
• Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017 Sep;48(9):2494–2503.
   PubMed Web of Science ®Google Scholar
• Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet. 2016 Aug 20;388(10046):806–817.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Molteni M, Cimminiello C. Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thromb J. 2014 Feb 18;12(1):5.
   PubMedGoogle Scholar